Omnitrope's Off-Label Future
When Sarah Sellers heard on May 31 that the U.S. Food & Drug Administration had approved a generic-like version of human growth hormone (HGH), she was less than thrilled. The product, called Omnitrope and made by a unit of Novartis (NVS), is the first low-cost, copycat biotech drug to be approved by the FDA.
To continue reading this article you must be a Bloomberg Professional Service Subscriber.
If you believe that you may have received this message in error please let us know.